Taking febuxostat to lower uric acid patients with uric acid reduced to 250μmol / L, it is still recommended to the smallest dose of maintenance for a period of time, in order to avoid sudden discontinuation of the drug uric acid rebound elevation. It is generally not recommended that long-term patients taking febuxostat to reduce uric acid in the uric acid lowering of patients to stop taking the drug in order to avoid uric acid rebound elevation, the patient’s blood uric acid 250 μmol / L has reached the uric acid control range, you can continue to minimize the dose of febuxostat to maintain the treatment for a period of time, to maintain the specific time by the doctor according to the condition of the assessment. Common adverse drug reactions to febuxostat are nausea, arthralgia, rash, and liver function abnormalities. The use of Febuxostat is contraindicated in patients with a history of hypersensitivity to the components of the product, patients undergoing treatment with azathioprine, mercaptopurine. Precautions: long-term use of febuxostat to lower uric acid patients need to be regularly to the hospital to monitor liver and renal function, and febuxostat may be with the cytarabine class of drugs, theophylline class of drugs and cytotoxic drugs in the existence of drug interactions, the use of febuxostat during the treatment of the general do not recommend the use of these drugs. Common adverse drug reactions to febuxostat are nausea and arthralgia. Drugs need to be used under the guidance of a physician, it is recommended that patients taking febuxostat tablets to the regular hospital rheumatology and immunology department and other related departments for consultation.